Zoledronic acid in people on dialysis
Part of Bones, joints & muscles, Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial studies how the drug zoledronic acid (used for bone loss) works in people with kidney disease who are on dialysis. It aims to help treat osteoporosis (weak bones) safely in this group.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older
- You must have chronic kidney disease and be on dialysis
- You must have osteoporosis (weakened bones) related to your kidney disease
- Your kidney function must be at least a certain level (eGFR of 35 or higher)
- You cannot be pregnant, breastfeeding, or plan to become pregnant
- You must not have taken zoledronic acid or similar drugs before
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether zoledronic acid or denosumab can prevent bone thinning in critically ill adults after staying in the ICU. It may help reduce the risk of future bone fractures if your body is at higher risk during and after critical illness.
This study tests whether an osteoporosis medication can help preserve muscle strength in older adults who live in senior facilities. It's for people age 65+ with fragile bones or low bone density who are at risk for falls and fractures.
This study compares two medicines (ibandronate and zoledronic acid) to see which one works better at keeping bones strong after stopping denosumab (Prolia). It's for postmenopausal women with mild to moderate bone thinning.
This trial tests if it's safe to switch from a long-term osteoporosis medication called Prolia to another treatment. It may help women and men who have been on Prolia for at least 3 years.
This trial aims to improve how primary care and hospital care work together to treat osteoporosis after a hip fracture. It may help by making follow-up treatment plans and communication clearer after your hip injury.
This study tests whether zoledronic acid, a medicine given by IV, helps prevent bone problems in women with breast cancer that has spread to the bones. It looks at how well the drug works in a real-world setting to reduce the risk of fractures or other bone issues.
Hear when a new Chronic kidney disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.